Netherlands Heart Journal最新文献

Background: To detect recurrent atrial fibrillation (AF) after pulmonary vein isolation (PVI), different methods can be used, ranging from incidental electrocardiograms (ECGs) to rhythm monitoring with implantable loop recorders. We investigated whether telemonitoring (TM) with photoplethysmography (PPG) is feasible for post-PVI follow-up.

Methods: In total, 157 pre-PVI patients were included. Of them, 78 underwent TM at a virtual AF clinic, for which they received a PPG application and were monitored by trained eNurses. The numbers of hospital contacts, hospital visits, ECGs and Holter recordings were assessed. Patient satisfaction and quality of life were analysed. Comparisons were made with a historical control group with a traditional follow-up of outpatient visits, ECGs and Holter recordings (n = 79).

Results: Mean ± standard deviation (SD) age was 63 ± 10 years, and 64% were male. AF was paroxysmal in 68% of the patients. Follow-up at 1 year was completed in all patients. In the TM group, the mean ± SD annual number of recordings per patient was 16 ± 29, and AF was detected in 37 patients (47%). The TM group experienced significant decreases in the numbers of unplanned outpatient clinic visits and AF-related hospital admissions, as well as reductions in the numbers of ECGs and Holter recordings performed. Patients reported high satisfaction with this form of TM.

Conclusion: The use of a virtual AF clinic was feasible, and satisfaction was high. Compared with patients with a traditional follow-up, patients on PPG-based TM needed fewer hospital visits and admissions and underwent fewer ECGs and Holter recordings.

Objectives: Coronary graft failure (CGF) may occur early after coronary bypass graft surgery (CABG). The study aimed to identify clinical and perioperative risk factors and to evaluate the long-term clinical impact of symptomatic early CGF.

Methods: Patients who underwent clinically indicated coronary angiography (CAG) prior to post-CABG discharge between 2012 and 2022 were included. Symptomatic early CGF was defined as a dysfunctional coronary graft, evaluated on clinically indicated CAG, caused by stenosis of the proximal or distal anastomosis or bypass conduit, bypass occlusion, thrombosis, reduced flow (TIMI < 1) and kinking/tenting. Patients were divided into symptomatic early CGF and non-early CGF groups. Kaplan-Meier and multivariate analysis estimated cumulative survival free of major adverse cardiovascular events (MACE: death, myocardial infarction and revascularisation) up to 5 years' follow-up and identified predictors of symptomatic early CGF.

Results: A total of 92 patients (79% male, 66.1 ± 10 years old) were included, of whom 55 (59.8%) had symptomatic early CGF. Baseline characteristics, surgical parameters and post-surgical parameters potentially indicative of ischaemia were comparable between groups. Patients with symptomatic early CGF had a significantly lower MACE rate over a median follow-up period of 33 months (p = 0.023). Venous graft integration (p = 0.005), Y‑graft configuration (p = 0.002) and prolonged inotropic support (p = 0.032) were associated with symptomatic early CGF.

Conclusions: Symptomatic early CGF was observed in the majority of post-CABG patients undergoing clinically indicated CAG prior to discharge. Patients with symptomatic early CGF exhibited higher MACE rates over a median follow-up period of 33 months. Venous graft integration, Y‑graft configuration and prolonged use of inotropic agents were associated with symptomatic early CGF. However, these clinical findings should be interpreted with caution.

Introduction: In patients undergoing percutaneous coronary intervention (PCI), personalised medicine is key to the secondary prevention of ischaemic and bleeding events. To provide an extensive overview of the quality of secondary prevention and of personalised medicine, a consortium in the southeastern region of the Netherlands has created a PCI registry: the South-East Netherlands Heart Registry (Zuid-Oost Nederland Hart Registratie, ZON-HR).

Aim: To visualise and improve personalised secondary prevention post-PCI, focussing on key elements such as antiplatelet treatment, cholesterol management and comorbidities such as diabetes mellitus.

Design and population: A prospective multicentre registry of all consecutive patients undergoing PCI at 4 participating PCI centres and 3 referral centres.

Treatment: Interventional procedures and concomitant pharmaceutical treatment are performed in accordance with the guidelines. The ZON-HR promotes risk stratification after PCI using a simplified protocol for a personalised antiplatelet strategy.

Data collection and quality: Demographics, laboratory values, baseline procedural characteristics and pharmaceutical treatment data are collected. Outcomes include thromboembolic and bleeding complications and medication changes. Data are pseudonymised, and a clinical event committee will review 20% of the adverse events (randomly selected).

Strengths and weaknesses: This registry represents the entire PCI population and visualises gaps in secondary prevention. Weaknesses are the collection of outcomes and medication changes using mostly patient-reported outcomes.

Conclusion: The ZON-HR is a comprehensive PCI registry that provides baseline and follow-up data of a large PCI cohort in the southeastern region of the Netherlands. The ZON-HR aims to improve secondary prevention after PCI and augment personalised treatment that focusses on key elements of secondary prevention.